Clinical Trial Update: Abilify Therapy for Reducing Comorbid Substance Abuse [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating aripiprazole (Abilify) for reducing comorbid substance use across multiple psychiatric disorders; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Bipolar Disorder
• Major Depressive Disorder
• Schizoaffective Disorder
• Schizophrenia
• Substance Use Disorder

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: Creighton University | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: COMPLETED